What sets this review apart from prior publications is its comprehensive focus on the broad spectrum of pleiotropic effects of SGLT2 inhibitors and their potential repurposing for diverse therapeutic applications beyond diabetes and cardiovascular diseases. The gene discussed is SLC5A2; the disease is diabetes mellitus.